The U.S. Food and Drug Administration has granted fast track status to FLX-787, Flex Pharma‘s treatment for severe muscle…
Articles by Margarida Azevedo, MSc
We know dealing with amyotrophic lateral sclerosis (ALS) sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like…
Brainstorm Cell Therapeutics has received a $16 million grant from a state agency known as the California Institute for Regenerative…
The Orlando-area medical marijuana company Green Relief is reminding Florida residents that the state no longer requires a 90-day waiting period…
Ipsen Biopharmaceuticals has entered an exclusive three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA), a therapy…
Mitsubishi Tanabe Pharma America (MT Pharma America) has enrolled more than 700 sites of…
Measuring neurofilaments in brain and spinal fluid appears to be a reliable way of confirming an ALS diagnosis, Belgian and German…
The Israel Innovation Authority (IIA) has awarded BrainStorm Cell Therapeutics a $2.1…
The U.S. Food and Drug Administration has expanded its approval of Dysport (abobotulinumtoxinA) as a treatment for spasticity in adults…
Flex Pharma, which develops therapies to reduce the cramps and shaking that are hallmarks of ALS and other neurological…